Literature DB >> 12621391

Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.

Xiao-Ping Chen1, Zhi-Rong Tan, Song-Lin Huang, Zheng Huang, Dong-Sheng Ou-Yang, Hong-Hao Zhou.   

Abstract

OBJECTIVE: This study was designed to define the effect of low-dose aspirin administration on the activity of cytochrome P450 (CYP) in normal human subjects.
METHODS: Aspirin, 50 mg daily, was given for 14 days to 18 nonsmoking healthy male volunteers. A modified 5-drug cocktail procedure consisting of caffeine, mephenytoin, metoprolol, chlorzoxazone, and midazolam was performed to simultaneously assess in vivo activity of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and CYP3A, respectively. The activities were assessed on 4 occasions including at baseline, after 7 and 14 daily doses of aspirin, and at 7 days after discontinuation of aspirin. Concentrations of parent drugs and corresponding metabolites in biologic samples were assayed by reversed-phase HPLC.
RESULTS: Both 7-day and 14-day aspirin intake increased the activity of CYP2C19 significantly, as indicated by 4-hydroxymephenytoin urinary recovery (P <.001). Induction of low-dose aspirin on CYP2C19 was time-dependent. CYP3A activity indices increased moderately but significantly by both 7-day and 14-day aspirin treatment (P <.05), but the percentage changes in CYP3A activity indices were not significant. Low-dose aspirin had no effect on CYP1A2, CYP2D6, and CYP2E1 in vivo activity by either 7-day or 14-day treatment.
CONCLUSIONS: The effect of low-dose aspirin on CYPs was enzyme-specific. Both 7-day and 14-day low-dose aspirin induced the in vivo activities of CYP2C19 but did not affect the activities of CYP1A2, CYP2D6, and CYP2E1. The effect of low-dose aspirin on CYP3A activity awaits further confirmation. When low-dose aspirin is used in combination with drugs that are substrates of CYP2C19, doses of the latter should be adjusted to ensure their efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621391     DOI: 10.1067/mcp.2003.14

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

2.  Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450.

Authors:  Mirza Bojić; Carl A Sedgeman; Leslie D Nagy; F Peter Guengerich
Journal:  Eur J Pharm Sci       Date:  2015-03-31       Impact factor: 4.384

3.  Repeated administration of berberine inhibits cytochromes P450 in humans.

Authors:  Ying Guo; Yao Chen; Zhi-Rong Tan; Curtis D Klaassen; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2011-08-26       Impact factor: 2.953

4.  Aspirin abrogates impairment of mammary gland differentiation induced by early in life second-hand smoke in mice.

Authors:  Julia Santucci-Pereira; Thomas J Pogash; Aman Patel; Navroop Hundal; Maria Barton; Anna Camoirano; Rosanna T Micale; Sebastiano La Maestra; Roumen Balansky; Silvio De Flora; Jose Russo
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

5.  Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Authors:  Andrew T Chan; Ann G Zauber; Meier Hsu; Aurora Breazna; David J Hunter; Rebecca B Rosenstein; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Gastroenterology       Date:  2009-02-21       Impact factor: 22.682

6.  Drug-drug interaction discovery and demystification using Semantic Web technologies.

Authors:  Adeeb Noor; Abdullah Assiri; Serkan Ayvaz; Connor Clark; Michel Dumontier
Journal:  J Am Med Inform Assoc       Date:  2017-05-01       Impact factor: 4.497

Review 7.  Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.

Authors:  Zhi-Yu Wang; Meng Chen; Ling-Ling Zhu; Lu-Shan Yu; Su Zeng; Mei-Xiang Xiang; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2015-03-19       Impact factor: 2.423

Review 8.  Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles.

Authors:  Sherif M Shoieb; Mahmoud A El-Ghiaty; Ayman O S El-Kadi
Journal:  Emergent Mater       Date:  2020-11-17

9.  Aspirin Inhibition of Group VI Phospholipase A2 Induces Synthetic Lethality in AAM Pathway Down-Regulated Gingivobuccal Squamous Carcinoma.

Authors:  Kshama Pansare; Bhabani Mohanty; Ranjeeta Dhotre; Aafrin M Pettiwala; Saili Parab; Neha Gupta; Poonam Gera; Nilesh Gardi; Rucha Dugge; Priyanka Sahu; Ruby Alhans; Pradnya Kowtal; Pradip Chaudhari; Rajiv Sarin
Journal:  Cells       Date:  2021-12-30       Impact factor: 6.600

Review 10.  Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes.

Authors:  Young Hee Choi
Journal:  Pharmaceutics       Date:  2020-05-02       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.